Sort   by:  
 Page size 
ProteomicsTRMU Confers Resistance of Melanoma Cells to Vemurafenib through Modulating Mitochondrial Electron Transport Chain Activities
Melanoma is the fifth most common newly diagnosed cancer in the U.S., where substitution of valine 600 with glutamic acid (V600E) in BRAF is the most frequently observed mutation in melanoma. Vemurafenib is an FDA-approved kinase inhibitor for BRAFV600E; while the drug can elicit effective remission...
ORGANISM(S): Homo sapiens (Human) 
2025-12-08 | PXD063781 | Pride
Vemurafenib resistance Mitochondrion Melanoma 
ModelsGiani2019 - Computational modeling to predict MAP3K8 effects as mediator of resistance to vemurafenib in thyroid cancer stem cells
Computational modeling to predict MAP3K8 effects as mediator of resistance to vemurafenib in thyroid cancer stem cells
2024-09-02 | BIOMD0000000883 | BioModels
TranscriptomicsRNA-Sequencing of vemurafenib-sensitive and resistant melanoma cell line SKMEL-239
RNA-seq data were generated for two conditions: for parental SK-MEL-239 cells grown in normal media and resistant SK-MEL-239 cells grown in media supplemented with vemurafenib.
ORGANISM(S): Homo sapiens 
2022-04-16 | E-MTAB-11609 | biostudies-arrayexpress
ProteomicsEzrin inhibition overcomes acquired resistance to vemurafenib in BRAFV600E-mutated colon cancer and melanoma cells in vitro
In spite of the advancements in targeted therapy for BRAFV600E-mutated metastatic colorectal cancer (mCRC), the development of resistance to BRAFV600E inhibition limits the response rate and durability of the treatment. Better understanding of the resistance mechanisms to BRAF inhibitors will facili...
ORGANISM(S): Homo sapiens (Human) 
2023-08-29 | PXD042499 | Pride
Ezrin Brafv600e Actin cytoskeleton Nsc305787 Colon cancer Ezrin inhibitor Melanoma Braf inhibitor Vemurafenib 
ProteomicsQuantitative proteomics links the intermediate filament nestin to vemurafenib resistance in melanoma cell lines
Targeted inhibition of mutated kinases using selective MAP kinase inhibitors in malignant melanoma often results in temporary improvement of the metastatic disease followed by rapid development of resistance. To gain insights in molecular processes that govern resistance, we performed SILAC-based qu...
ORGANISM(S): Homo sapiens (Human) 
2019-05-14 | PXD010683 | Pride
Cytoskeletal proteins Mass spectrometry Drug resistance Melanoma 
ProteomicsMolecular dynamics of acquired vemurafenib-resistance in dogs with naturally ocurring BRAF-mutated Urothelial Carcinoma
Dogs treated with Vemurafenib were surveyed for naturally aquired drug resistance using proteomics and phosphoproteomics
ORGANISM(S): Canis familiaris (Dog) (Canis lupus familiaris) 
2026-01-01 | PXD062194 | Pride
Dog Braf-mutated carcinoma Urothelial carcinoma 
TranscriptomicsA new ALK isoform transported by extracellular vesicles confers drug resistance to vemurafenib in A375 melanoma cells
Despite the successful use of drugs targeting the MAPK signaling pathway and immunotherapy in melanoma, the majority of patients with metastatic disease still undergo disease progression indicating a gradual development of therapy resistance. In the present study, microarray analyses were performed ...
ORGANISM(S): Homo sapiens 
2019-02-28 | E-MTAB-6596 | biostudies-arrayexpress
GenomicsVemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
PRJNA862390 | ENA
GenomicsVemurafenib, BRAF inhibitor, Resistance in BRAFV600E Positive Thyroid Cancer cell lines
Vemurafenib, BRAF inhibitor, Resistance in BRAFV600E Positive Thyroid Cancer cell lines
PRJNA738167 | ENA
TranscriptomicsSpectrum, clinical correlates and clinical implications of BRAF-inhibitor resistance mechanisms in melanoma
Multiple BRAF inhibitor resistance mechanisms have been described, however their relative frequency, clinical correlates, and effect on subsequent therapy have not been assessed in patients with metastatic melanoma. Excised progressing BRAFV600 mutant melanoma metastases (Prog) from patients treated...
ORGANISM(S): Homo sapiens 
2014-02-19 | E-GEOD-50509 | biostudies-arrayexpress
Sort   by:  
 Page size